#United States #Pleasanton #Atera #10x Genomics #Sentira

10x Genomics Reports Third Quarter 2026 Financial Results

10x Genomics, a prominent player in life science technologies, announced its financial results for the third quarter of 2026 on November 5. The company, known for its focus on advancing human health and scientific research, reported a revenue of $150.7 million—1% higher than the same period last year. This modest growth is attributed to the increasing popularity of their product offerings and a strong demand for their consumables.

Key Highlights of Q3 2026

The most notable achievement during this quarter was the commencement of global commercial shipments of their new platform, Atera. The early demand exceeded expectations by instigating ambitious research initiatives across various fields, including discovery, translational research, and biopharma sectors.

Additionally, Sentira, their latest cloud analysis tool, was introduced to help researchers convert complex biological data into actionable insights. This innovative platform leverages NVIDIA's accelerated computing capabilities for efficient spatial data processing and incorporates Anthropic's Claude for deep analysis of single-cell data. CEO Serge Saxonov expressed strong optimism about the enthusiasm surrounding these launches, suggesting that 10x Genomics is strategically positioned to lead in this era of advanced data analytics in biological research.

Financial Insights

For Q3 2026, 10x Genomics reported:

• - Revenue: $150.7 million compared to $149.0 million in Q3 2025.
• - Gross Margin: An increase to 75%, up from 67% a year earlier, largely due to lower inventory write-downs and improved product mix.
• - Operating Expenses: Reduced to $129 million from $132.5 million, reflecting lower personnel costs and lab expenses, despite some increases in litigation costs.
• - Operating Loss: Decreased to $16.1 million from $32.2 million year-over-year.
• - Net Loss: Reduced to $19.4 million versus $27.5 million for the same period last year.

Cash reserves stood at $575.7 million as of September 30, providing a strong financial foundation for ongoing operations and future investments.

Revised Financial Guidance for 2026

In a positive shift, 10x Genomics has adjusted its full-year revenue guidance upward, now expecting totals between $625 million to $635 million, up from previous estimates of $610 million to $630 million. This revision signifies an anticipated growth of 4% to 6% over fiscal year 2025, excluding any one-off revenues from patents and litigation settlements.

Looking Forward

10x Genomics will be hosting a conference call on November 5 at 1:30 PM PT to delve deeper into their financial results, discuss recent business developments, and share insights on future prospects. This call will be accessible via their investor relations website, providing stakeholders an opportunity to engage directly with the company's leadership.

As advancements in artificial intelligence and data processing revolutionize the biological sciences, 10x Genomics stands at the forefront, committed to accelerating research and enhancing our understanding of health and disease through innovative technologies and strategic growth initiatives.

For the latest updates, visit their official website or connect through their social media channels. 10x Genomics continues to evolve, and as they transition to a data-driven future, they remain dedicated to delivering products that cater to the intricate needs of researchers and biopharmaceutical companies.

Conclusion

In summary, 10x Genomics is navigating a promising chapter marked by rising revenues, groundbreaking product launches, and a robust outlook for future growth. As they continue to enhance their offerings, the focus remains on leveraging technology to transform biological research and, ultimately, improve health outcomes worldwide.